Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Myelodysplastic Syndromes • Leukemia • Internal Medicine • Hematology
What is the best strategy after initial treatment with hypomethylating agents for high grade myelodysplatic syndromes, mainly for responders who became transfusion independent?
Do we continue the hypomethylating agent indefinitely?
Answer from: Medical Oncologist at Academic Institution
The hypomethylating agents (HMA’s, 5-azacitidine & decitabine) have important disease modifying properties in addition to relieving cytopenias for patients with high-risk MDS. They decrease the risk of progression to leukemia and improve overall survival. The randomized phase I...
Sign in or Register to read more